Who is sponsoring NCT00737438?

NCT00737438 is sponsored by Memorial Sloan Kettering Cancer Center.

What condition does NCT00737438 study?

NCT00737438 studies Esophageal Cancer, Gastric Cancer.

What drugs are being tested in NCT00737438?

Interventions: epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan.

What is the status of NCT00737438?

NCT00737438 is currently COMPLETED.

Last reviewed 2016-01-04 · How we verify

A Phase II Study of Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

NCT00737438 Phase 2 COMPLETED Results posted

This study is being done to find out how effective a new treatment strategy is on your cancer. In this strategy, the response your tumor has to the first cycle of therapy will help select the next treatments. We also will find out the effects, both good and/or bad, a drug called bevacizumab has on you and your tumor when given with chemotherapy.

Details

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 2
Status	COMPLETED
Enrolment	22
Start date	2008-08
Completion	2015-02

Conditions

Esophageal Cancer
Gastric Cancer

Interventions

epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan

Primary outcomes

Overall Response Will be Characterized by the Patient's FDG-PET Scan — 2 years
A good early FDG Response is a reduction in FDG uptake on the week 3 PET scan of \> or = to 35% from baseline. An FDG PET non-responder will be defined as having a decrease of \< 35% on the week 3 PET scan compared with baseline.

Countries

United States